The Theory and Practice of Financial Engineeringby Paul Wilmott
Usually ships within 2 to 4 working days
Description of DerivativesACE inhibitors are justly regarded as the most important advance in cardiac drug therapy since the advent of calcium channel antagonist drugs. Acting basically as inhibitors of the renin–angiotensin vasoconstrictor system, these agents have grown in importance to become among the therapeutic agents first choice for hypertension and a cornerstone of therapy in congestive heart failure. Recent studies show that they can also prevent overt heart failure and reinfarction, and beneficially influence diabetic renal lesions. The major aim of Angiotensin–Converting Enzyme Inhibitors: Scientific Basis for Clinical Use is to present the clinician with the information needed for the practical and discerning use of ACE inhibitors. When do these agents really work and in what doses? Which claims are based on promotional material and which claims have relevance for the clinician in the practical treatment of hypertension, heart failure or myocardial infarction? This Second Edition adds new material that critically reviews the recent large trials including Consensus–II, Save, V–HeFT–II, Aire, and ISIS–IV and guides the clinician toward a rational policy of use. There is an important new chapter on the use of ACE inhibitors in the metabolic cardiovascular syndrome and in diabetic nephropathy. Reviews of Other Books by the Author Drugs for the Heart—"A gem" (New England Journal of Medicine) The Heart—"The subjects are brilliantly illuminated and made exciting by excellent line diagrams" (The Lancet) Reviews of First Edition of this Book "A new milestone" (British Medical Journal) "Pathophysiology is clarified by numerous diagrams in a style well–known from Opie’s former books" (The Lancet)
Write a review of this book
Customer Reviews from Amazon
About Paul WilmottLionel H. Opie, M.D., Ph.D., is Professor of Medicine at the University of Cape Town. After graduating from the University of Cape Town, he studied at Oxford as a Rhodes Scholar and was a Research Fellow at Harvard from 1959-1961. He became a Fellow of the Royal College of Physicians of London in 1974. From 1976-1978, he was President of the International Society for Heart Research. He is the author of The Heart: Physiology and Metabolism, Second Edition, 1991, and Myocardial Protection by Calcium Antagonists, 1994. He is Editor of Drugs for the Heart, Fourth Edition in preparation for 1995. He is Co–Editor of Cardiovascular Drugs and Therapy. For 1990-1993, he was Chairman of the Committee on Cardiovascular Drugs of the International Society and Federation of Cardiology. In 1992, he was Visiting Professor and British Heart Foundation Senior Fellow, St. Thomas′ Hospital, London. For 1984–1994, he was Visiting Professor, Division of Cardiovascular Medicine, Stanford University Medical Center, California.